The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1551
July 16, 2018
View Complete Issue         Table of Contents 2019 
Lofexidine (Lucemyra) for Opioid Withdrawal
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lofexidine (Lucemyra) for Opioid Withdrawal
July 16, 2018 (Issue: 1551)
The FDA has approved lofexidine (Lucemyra – US WorldMeds/Salix), a centrally acting alpha2 receptor agonist, to manage withdrawal symptoms in adults abruptly stopping opioid use. Available in the UK since 1992, lofexidine is the first nonopioid...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lofexidine (Lucemyra) for Opioid Withdrawal
Article code: 1551a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.